Our findings reveal a key role of SLC39A1‐DRP1 interaction in HCC progression by disturbing mitochondrial quality control and providing a competitive peptide as a potential anti‐tumour therapy. This evidence concerns the gene SLC39A1 and hepatocellular carcinoma.